GlassScriptPhysician profile
Nabil Nouna
NPI 1770540205
$16,604.04
in general payments reported to CMS, 2019-2025
55 companies · $3,201 in 2025
The $3,201 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,965 · 2020: $1,867 · 2021: $2,357 · 2022: $2,378 · 2023: $2,453 · 2024: $2,385 · 2025: $3,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,037.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,038.59 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,716.00 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,224.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $967.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $953.27 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Amgen INC. | $888.45 | 2019-2025 | Evenity, Prolia, Otezla |
| Astellas Pharma US INC | $775.00 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $732.18 | 2019-2025 | |
| Grifols USA, LLC | $694.93 | 2019-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $670.08 | 2021-2025 | |
| Lilly USA, LLC | $525.40 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $455.45 | 2019-2025 | |
| Lundbeck LLC | $441.14 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $311.78 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $297.68 | 2020-2025 | Capvaxive, Vaxneuvance, Pneumovax 23 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Nouna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.